BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Galli R, Starace D, Busà R, Angelini DF, Paone A, De Cesaris P, Filippini A, Sette C, Battistini L, Ziparo E. TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J Immunol. 2010;184:6658-6669. [PMID: 20483744 DOI: 10.4049/jimmunol.0902401] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Edinger N, Lebendiker M, Klein S, Zigler M, Langut Y, Levitzki A. Targeting polyIC to EGFR over-expressing cells using a dsRNA binding protein domain tethered to EGF. PLoS One 2016;11:e0162321. [PMID: 27598772 DOI: 10.1371/journal.pone.0162321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Alvarado AG, Lathia JD. Taking a Toll on Self-Renewal: TLR-Mediated Innate Immune Signaling in Stem Cells. Trends Neurosci 2016;39:463-71. [PMID: 27155992 DOI: 10.1016/j.tins.2016.04.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
3 Yang X, Chen GT, Wang YQ, Xian S, Zhang L, Zhu SM, Pan F, Cheng YX. TLR4 promotes the expression of HIF-1α by triggering reactive oxygen species in cervical cancer cells in vitro-implications for therapeutic intervention. Mol Med Rep 2018;17:2229-38. [PMID: 29207048 DOI: 10.3892/mmr.2017.8108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
4 Galli R, Paone A, Fabbri M, Zanesi N, Calore F, Cascione L, Acunzo M, Stoppacciaro A, Tubaro A, Lovat F, Gasparini P, Fadda P, Alder H, Volinia S, Filippini A, Ziparo E, Riccioli A, Croce CM. Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARβ and tumor regression. Proc Natl Acad Sci U S A 2013;110:9812-7. [PMID: 23716670 DOI: 10.1073/pnas.1304610110] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
5 Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 2011;71:2466-75. [PMID: 21427357 DOI: 10.1158/0008-5472.CAN-10-1993] [Cited by in Crossref: 128] [Cited by in F6Publishing: 70] [Article Influence: 12.8] [Reference Citation Analysis]
6 Walshaw RC, Honeychurch J, Choudhury A, Illidge TM. Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control. Int J Radiat Oncol Biol Phys 2020;108:27-37. [PMID: 32339645 DOI: 10.1016/j.ijrobp.2020.04.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Han JH, Park JH, Kim BY, Chang SN, Kim TH, Park JH, Kim DJ. Decreased expression of Toll-like receptor 4 and 5 during progression of prostate transformation in transgenic adenocarcinoma of mouse prostate mice. J Vet Sci 2015;16:281-7. [PMID: 25797291 DOI: 10.4142/jvs.2015.16.3.281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Yu L, Wang L, Chen S. Dual character of Toll-like receptor signaling: pro-tumorigenic effects and anti-tumor functions. Biochim Biophys Acta 2013;1835:144-54. [PMID: 23232186 DOI: 10.1016/j.bbcan.2012.10.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
9 Zhao X, Ai M, Guo Y, Zhou X, Wang L, Li X, Yao C. Poly I:C-induced tumor cell apoptosis mediated by pattern-recognition receptors. Cancer Biother Radiopharm 2012;27:530-4. [PMID: 23062195 DOI: 10.1089/cbr.2012.1226] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
10 Tarang S, Kumar S, Batra SK. Mucins and toll-like receptors: kith and kin in infection and cancer. Cancer Lett 2012;321:110-9. [PMID: 22306702 DOI: 10.1016/j.canlet.2012.01.040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
11 Schau I, Michen S, Hagstotz A, Janke A, Schackert G, Appelhans D, Temme A. Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis. Sci Rep 2019;9:3299. [PMID: 30824859 DOI: 10.1038/s41598-019-40032-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
12 Seelige R, Searles S, Bui JD. Mechanisms regulating immune surveillance of cellular stress in cancer. Cell Mol Life Sci 2018;75:225-40. [PMID: 28744671 DOI: 10.1007/s00018-017-2597-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
13 Langut Y, Edinger N, Flashner-Abramson E, Melamed-Book N, Lebendiker M, Levi-Kalisman Y, Klein S, Levitzki A. PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses. Oncotarget 2017;8:24046-62. [PMID: 28445962 DOI: 10.18632/oncotarget.15733] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
14 Cobaleda-Siles M, Henriksen-Lacey M, Ruiz de Angulo A, Bernecker A, Gómez Vallejo V, Szczupak B, Llop J, Pastor G, Plaza-Garcia S, Jauregui-Osoro M, Meszaros LK, Mareque-Rivas JC. An iron oxide nanocarrier for dsRNA to target lymph nodes and strongly activate cells of the immune system. Small 2014;10:5054-67. [PMID: 25123704 DOI: 10.1002/smll.201401353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 0.4] [Reference Citation Analysis]
15 Wang S, Clarke PAG, Davis R, Mumuni S, Kwabi-Addo B. Sex steroid-induced DNA methylation changes and inflammation response in prostate cancer. Cytokine 2016;86:110-8. [PMID: 27500645 DOI: 10.1016/j.cyto.2016.07.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
16 Gujar SA, Pan DA, Marcato P, Garant KA, Lee PW. Oncolytic virus-initiated protective immunity against prostate cancer. Mol Ther. 2011;19:797-804. [PMID: 21245852 DOI: 10.1038/mt.2010.297] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
17 Nischalke HD, Berger C, Lutz P, Langhans B, Wolter F, Eisenhardt M, Krämer B, Kokordelis P, Glässner A, Müller T, Rosendahl J, Fischer J, Berg T, Grünhage F, Leifeld L, Soyka M, Nattermann J, Sauerbruch T, Stickel F, Spengler U. Influence of the CXCL1 rs4074 A allele on alcohol induced cirrhosis and HCC in patients of European descent. PLoS One 2013;8:e80848. [PMID: 24260493 DOI: 10.1371/journal.pone.0080848] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
18 Zhao S, Zhang Y, Zhang Q, Wang F, Zhang D. Toll-like receptors and prostate cancer. Front Immunol 2014;5:352. [PMID: 25101092 DOI: 10.3389/fimmu.2014.00352] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
19 Gatti G, Nuñez NG, Nocera DA, Dejager L, Libert C, Giraudo C, Maccioni M. Direct effect of dsRNA mimetics on cancer cells induces endogenous IFN-β production capable of improving dendritic cell function. Eur J Immunol 2013;43:1849-61. [PMID: 23636788 DOI: 10.1002/eji.201242902] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
20 Rezania S, Amirmozaffari N, Rashidi N, Mirzadegan E, Zarei S, Ghasemi J, Zarei O, Katouzian L, Zarnani AH. The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation. Cancer Cell Int 2014;14:54. [PMID: 24966802 DOI: 10.1186/1475-2867-14-54] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
21 Sun M, Geng D, Li S, Chen Z, Zhao W. LncRNA PART1 modulates toll-like receptor pathways to influence cell proliferation and apoptosis in prostate cancer cells. Biol Chem 2018;399:387-95. [PMID: 29261512 DOI: 10.1515/hsz-2017-0255] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
22 Alvarado-Morales I, Olivares-Illana V, Arenas-Huertero C, Reynaga-Hernández E, Layseca-Espinosa E, Tokar EJ, Escudero-Lourdes C. Human prostate epithelial cells and prostate-derived stem cells malignantly transformed in vitro with sodium arsenite show impaired Toll like receptor -3 (TLR3)-associated anti-tumor pathway. Toxicol Lett 2021;350:185-93. [PMID: 34303791 DOI: 10.1016/j.toxlet.2021.07.013] [Reference Citation Analysis]
23 Miyauchi K, Urano E, Takeda S, Murakami T, Okada Y, Cheng K, Yin H, Kubo M, Komano J. Toll-like receptor (TLR) 3 as a surrogate sensor of retroviral infection in human cells. Biochem Biophys Res Commun 2012;424:519-23. [PMID: 22771581 DOI: 10.1016/j.bbrc.2012.06.148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
24 Fabbri M, Paone A, Calore F, Galli R, Croce CM. A new role for microRNAs, as ligands of Toll-like receptors. RNA Biol. 2013;10:169-174. [PMID: 23296026 DOI: 10.4161/rna.23144] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 12.4] [Reference Citation Analysis]
25 Mett V, Komarova EA, Greene K, Bespalov I, Brackett C, Gillard B, Gleiberman AS, Toshkov IA, Aygün-Sunar S, Johnson C, Karasik E, Bapardekar-Nair M, Kurnasov OV, Osterman AL, Stanhope-Baker PS, Morrison C, Moser MT, Foster BA, Gudkov AV. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene 2018;37:439-49. [PMID: 28967901 DOI: 10.1038/onc.2017.346] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
26 Han JH, Park SY, Kim JB, Cho SD, Kim B, Kim BY, Kang MJ, Kim DJ, Park JH, Park JH. TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells. Am J Reprod Immunol 2013;70:317-26. [PMID: 23790156 DOI: 10.1111/aji.12146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kutikhin AG. Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol. 2011;72:1095-1116. [PMID: 21872627 DOI: 10.1016/j.humimm.2011.07.307] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
28 Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Rapoport AP, Ostrand-Rosenberg S, Davila E. TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. Cancer Res 2015;75:1959-71. [PMID: 25795705 DOI: 10.1158/0008-5472.CAN-14-2467] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
29 Zheng X, Li S, Yang H. Roles of Toll-Like Receptor 3 in Human Tumors. Front Immunol 2021;12:667454. [PMID: 33986756 DOI: 10.3389/fimmu.2021.667454] [Reference Citation Analysis]
30 Patidar A, Selvaraj S, Sarode A, Chauhan P, Chattopadhyay D, Saha B. DAMP-TLR-cytokine axis dictates the fate of tumor. Cytokine 2018;104:114-23. [PMID: 29032985 DOI: 10.1016/j.cyto.2017.10.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
31 Gillgrass A, Ashkar A. Stimulating natural killer cells to protect against cancer: recent developments. Expert Review of Clinical Immunology 2014;7:367-82. [DOI: 10.1586/eci.10.102] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
32 Gambara G, De Cesaris P, De Nunzio C, Ziparo E, Tubaro A, Filippini A, Riccioli A. Toll-like receptors in prostate infection and cancer between bench and bedside. J Cell Mol Med. 2013;17:713-722. [PMID: 23551576 DOI: 10.1111/jcmm.12055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
33 Bernardo AR, Cosgaya JM, Aranda A, Jiménez-Lara AM. Pro-apoptotic signaling induced by Retinoic acid and dsRNA is under the control of Interferon Regulatory Factor-3 in breast cancer cells. Apoptosis 2017;22:920-32. [PMID: 28409399 DOI: 10.1007/s10495-017-1377-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
34 Kourko O, Smyth R, Cino D, Seaver K, Petes C, Eo SY, Basta S, Gee K. Poly(I:C)-Mediated Death of Human Prostate Cancer Cell Lines Is Induced by Interleukin-27 Treatment. J Interferon Cytokine Res 2019;39:483-94. [PMID: 31009295 DOI: 10.1089/jir.2018.0166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
35 Kim HJ, Park JW, Cho YS, Cho CH, Kim JS, Shin HW, Chung DH, Kim SJ, Chun YS. Pathogenic role of HIF-1α in prostate hyperplasia in the presence of chronic inflammation. Biochim Biophys Acta 2013;1832:183-94. [PMID: 22986049 DOI: 10.1016/j.bbadis.2012.09.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
36 Harashima N, Inao T, Imamura R, Okano S, Suda T, Harada M. Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother. 2012;61:667-676. [PMID: 22038398 DOI: 10.1007/s00262-011-1132-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
37 Zhang Y, Luo F, Li A, Qian J, Yao Z, Feng X, Chu Y. Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice. Clin Immunol 2014;154:26-36. [PMID: 24928324 DOI: 10.1016/j.clim.2014.06.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
38 Duan M, Wang ZC, Wang XY, Shi JY, Yang LX, Ding ZB, Gao Q, Zhou J, Fan J. TREM-1, an Inflammatory Modulator, is Expressed in Hepatocellular Carcinoma Cells and Significantly Promotes Tumor Progression. Ann Surg Oncol. 2015;22:3121-3129. [PMID: 25465376 DOI: 10.1245/s10434-014-4191-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
39 Fávaro WJ, Nunes OS, Seiva FR, Nunes IS, Woolhiser LK, Durán N, Lenaerts AJ. Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer. Infect Agent Cancer 2012;7:14. [PMID: 22709446 DOI: 10.1186/1750-9378-7-14] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
40 Yu L, Pham Q, Yu LL, Wang TTY. Modulation of CXC-motif chemokine receptor 7, but not 4, expression is related to migration of the human prostate cancer cell LNCaP: regulation by androgen and inflammatory stimuli. Inflamm Res 2020;69:167-78. [PMID: 31865399 DOI: 10.1007/s00011-019-01305-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Gambara G, Desideri M, Stoppacciaro A, Padula F, De Cesaris P, Starace D, Tubaro A, Del Bufalo D, Filippini A, Ziparo E, Riccioli A. TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo. J Cell Mol Med 2015;19:327-39. [PMID: 25444175 DOI: 10.1111/jcmm.12379] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
42 Craven KE, Gökmen-Polar Y, Badve SS. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. Sci Rep 2021;11:4691. [PMID: 33633150 DOI: 10.1038/s41598-021-83913-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
44 Misawa A, Takayama KI, Fujimura T, Homma Y, Suzuki Y, Inoue S. Androgen-induced lncRNA POTEF-AS1 regulates apoptosis-related pathway to facilitate cell survival in prostate cancer cells. Cancer Sci 2017;108:373-9. [PMID: 28032932 DOI: 10.1111/cas.13151] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
45 Yu M, Levine SJ. Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses. Cytokine Growth Factor Rev 2011;22:63-72. [PMID: 21466970 DOI: 10.1016/j.cytogfr.2011.02.001] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 11.3] [Reference Citation Analysis]
46 Sfanos KS, Hempel HA, De Marzo AM. The role of inflammation in prostate cancer. Adv Exp Med Biol. 2014;816:153-181. [PMID: 24818723 DOI: 10.1007/978-3-0348-0837-8_7] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
47 Kutikhin AG, Yuzhalin AE. The Biology of Toll-Like Receptors and NOD-Like Receptors: The Toggles of Inflammation. Genomics of Pattern Recognition Receptors. Basel: Springer; 2013. pp. 1-25. [DOI: 10.1007/978-3-0348-0688-6_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]